Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia.
Journal
Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462
Informations de publication
Date de publication:
03 Apr 2024
03 Apr 2024
Historique:
received:
09
08
2023
accepted:
01
03
2024
medline:
4
4
2024
pubmed:
4
4
2024
entrez:
3
4
2024
Statut:
aheadofprint
Résumé
Propionic acidaemia is a rare disorder caused by defects in the propionyl-coenzyme A carboxylase α or β (PCCA or PCCB) subunits that leads to an accumulation of toxic metabolites and to recurrent, life-threatening metabolic decompensation events. Here we report interim analyses of a first-in-human, phase 1/2, open-label, dose-optimization study and an extension study evaluating the safety and efficacy of mRNA-3927, a dual mRNA therapy encoding PCCA and PCCB. As of 31 May 2023, 16 participants were enrolled across 5 dose cohorts. Twelve of the 16 participants completed the dose-optimization study and enrolled in the extension study. A total of 346 intravenous doses of mRNA-3927 were administered over a total of 15.69 person-years of treatment. No dose-limiting toxicities occurred. Treatment-emergent adverse events were reported in 15 out of the 16 (93.8%) participants. Preliminary analysis suggests an increase in the exposure to mRNA-3927 with dose escalation, and a 70% reduction in the risk of metabolic decompensation events among 8 participants who reported them in the 12-month pretreatment period.
Identifiants
pubmed: 38570682
doi: 10.1038/s41586-024-07266-7
pii: 10.1038/s41586-024-07266-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Wongkittichote, P., Ah Mew, N. & Chapman, K. A. Propionyl-CoA carboxylase: a review. Mol. Genet. Metab. 122, 145–152 (2017).
doi: 10.1016/j.ymgme.2017.10.002
pubmed: 29033250
pmcid: 5725275
Ando, T., Rasmussen, K., Nyhan, W. L. & Hull, D. 3-hydroxypropionate: significance of beta-oxidation of propionate in patients with propionic acidemia and methylmalonic acidemia. Proc. Natl Acad. Sci. USA 69, 2807–2811 (1972).
doi: 10.1073/pnas.69.10.2807
pubmed: 4507604
pmcid: 389649
Ando, T., Rasmussen, K., Wright, J. M. & Nyhan, W. L. Isolation and identification of methylcitrate, a major metabolic product of propionate in patients with propionic acidemia. J. Biol. Chem. 247, 2200–2204 (1972).
doi: 10.1016/S0021-9258(19)45512-9
pubmed: 5016650
Baumgartner, M. R. et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J. Rare Dis. 9, 130 (2014).
doi: 10.1186/s13023-014-0130-8
pubmed: 25205257
pmcid: 4180313
Shchelochkov, O. A., Carrillo, N. & Venditti, C. Propionic acidemia. In GeneReviews (eds Adam, M. P. et al.) (Univ. Washington, 1993).
Fraser, J. L. & Venditti, C. P. Methylmalonic and propionic acidemias: clinical management update. Curr. Opin. Pediatr. 28, 682–693 (2016).
doi: 10.1097/MOP.0000000000000422
pubmed: 27653704
pmcid: 5393914
Haijes, H. A., Jans, J. J. M., Tas, S. Y., Verhoeven-Duif, N. M. & van Hasselt, P. M. Pathophysiology of propionic and methylmalonic acidemias. Part 1: complications. J. Inherit. Metab. Dis. 42, 730–744 (2019).
doi: 10.1002/jimd.12129
pubmed: 31119747
Forny, P. et al. Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: first revision. J. Inherit. Metab. Dis. 44, 566–592 (2021).
doi: 10.1002/jimd.12370
pubmed: 33595124
pmcid: 8252715
Vockley, J. et al. Challenges and strategies for clinical trials in propionic and methylmalonic acidemias. Mol. Genet. Metab. 139, 107612 (2023).
doi: 10.1016/j.ymgme.2023.107612
pubmed: 37245378
Jiang, L. et al. Dual mRNA therapy restores metabolic function in long-term studies in mice with propionic acidemia. Nat. Commun. 11, 5339 (2020).
doi: 10.1038/s41467-020-19156-3
pubmed: 33087718
pmcid: 7578066
Zabaleta, N., Torella, L., Weber, N. D. & Gonzalez-Aseguinolaza, G. mRNA and gene editing: late breaking therapies in liver diseases. Hepatology 76, 869–887 (2022).
doi: 10.1002/hep.32441
pubmed: 35243655
Szebeni, J., Simberg, D., Gonzalez-Fernandez, A., Barenholz, Y. & Dobrovolskaia, M. A. Roadmap and strategy for overcoming infusion reactions to nanomedicines. Nat. Nanotechnol. 13, 1100–1108 (2018).
doi: 10.1038/s41565-018-0273-1
pubmed: 30348955
pmcid: 6320688
Diaz-Manera, J. et al. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurol. 20, 1012–1026 (2021).
doi: 10.1016/S1474-4422(21)00241-6
pubmed: 34800399
El-Gharbawy, A. H. et al. An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusions. Mol. Genet. Metab. 104, 118–122 (2011).
doi: 10.1016/j.ymgme.2011.07.004
pubmed: 21802969
pmcid: 3711228
Yap, S., Vara, R. & Morais, A. Post-transplantation outcomes in patients with PA or MMA: a review of the literature. Adv. Ther. 37, 1866–1896 (2020).
doi: 10.1007/s12325-020-01305-1
pubmed: 32270363
pmcid: 7141097
Kremsner, P. G. et al. Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2: a phase 1 randomized clinical trial. Wien. Klin. Wochenschr. 133, 931–941 (2021).
doi: 10.1007/s00508-021-01922-y
pubmed: 34378087
pmcid: 8354521
Lawitz, E. J. et al. BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial. Hepatology 75, 912–923 (2022).
doi: 10.1002/hep.32181
pubmed: 34605045
Zhang, X. et al. Patisiran pharmacokinetics, pharmacodynamics, and exposure–response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin-mediated (hATTR) amyloidosis. J. Clin. Pharmacol. 60, 37–49 (2020).
doi: 10.1002/jcph.1480
pubmed: 31322739
An, D. et al. Systemic messenger RNA therapy as a treatment for methylmalonic acidemia. Cell Rep. 21, 3548–3558 (2017).
doi: 10.1016/j.celrep.2017.11.081
pubmed: 29262333
pmcid: 9667413
Sampson, H. A. et al. Second symposium on the definition and management of anaphylaxis: summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J. Allergy Clin. Immunol. 117, 391–397 (2006).
doi: 10.1016/j.jaci.2005.12.1303
pubmed: 16461139
Manivannan, V., Decker, W. W., Stead, L. G., Li, J. T. & Campbell, R. L. Visual representation of National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network criteria for anaphylaxis. Int. J. Emerg. Med. 2, 3–5 (2009).
doi: 10.1007/s12245-009-0093-z
pubmed: 19390910
pmcid: 2672985
Mao, X. et al. Ultrasensitive electrochemical detection of mRNA using branched DNA amplifiers. Electrochem. Commun. 10, 1847–1850 (2008).
doi: 10.1016/j.elecom.2008.09.028